Compare Repligen Corporation Common Stock (RGEN) vs Revolution Medicines Inc. Common Stock (RVMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Revolution Medicines Inc. Common Stock — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Revolution Medicines Inc. Common Stock trades at $193.15 (market cap $40.39B). The key difference: Revolution Medicines Inc. Common Stock is far larger — about 3.6× Repligen Corporation Common Stock's market cap, and Revolution Medicines Inc. Common Stock is more actively traded (2,941,009 versus 1,259,263). Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Revolution Medicines Inc. Common Stock for 2 Days on average.
| RGEN | RVMD | |
|---|---|---|
Market Cap | $11.14B | $40.39B |
Volume | 1,259,263 | 2,941,009 |
Sector | Health | Health |
52-Week High | $194.57 | $221.15 |
52-Week Low | $102.87 | $49.56 |
Typical Hold Time | 0 Days | 2 Days |
Enterprise Value | $11.02B | $37.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Revolution Medicines (RVMD) trades at $188.44, down 2.84% on the day, amid a bearish technical signal. The company reported no revenue in 2025, with a net loss of $1.13 billion, and has missed earnings expectations for three consecutive quarters. However, recent positive developments include the start of a Phase 3 trial for RASONQUE in pancreatic cancer and FDA Breakthrough Therapy Designation, fueling analyst optimism.
The outlook balances high-risk, high-reward potential. Strong analyst support (91.67% buy ratings) and a $253.35 consensus price target suggest significant upside, driven by the promising oncology pipeline. Key risks include substantial cash burn, lack of current revenue, and clinical trial execution uncertainties, making the stock suitable for investors comfortable with biotech volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Revolution Medicines Inc. Common Stock
Revolution Medicines develops precision medicines for cancer. Its programs focus on targeting RAS-driven cancers and related signaling pathways.
Read more on RVMD →
